Progress in anti-cancer target PARP7 and its inhibitors
10.12360/CPB202405026
- VernacularTitle:抗癌靶点PARP7及其抑制剂研究进展
- Author:
Zhen-yu ZHAO
1
;
Xiao-lu LU
1
;
Jian LI
1
Author Information
1. 赣南医科大学药学院,江西赣州 341000
- Publication Type:Journal Article
- Keywords:
PARPs;
PARP7;
monoPARPs;
IFN-1;
anticancer target;
PARP7 small molecule inhibitor
- From:
Chinese Pharmacological Bulletin
2025;41(4):620-625
- CountryChina
- Language:Chinese
-
Abstract:
PARP7 is a mono-ADP ribotransferase belonging to the PARP family that acts as a specific amino acid to catalyze the transfer of ADP ribose from NAD+to itself and other sub-strate proteins.PARP7 is overactive in many tumors and can in-terfere with interferon signaling pathways to enable cancer cells to achieve immune escape.Inhibition of PARP7 can restore IFN-β expression in tumor cells,thereby activating T cell-mediated anti-tumor immunity in vivo,so PARP7 is considered as a new immunomodulatory target for cancer therapy.At present,only one selective inhibitor of PARP7,RBN-2397,has entered phaseⅠ clinical studies.This article focuses on the structure and bio-logical function of PARP7,the correlation between PARP7 and cancer occurrence,and the research progress of PARP7-related inhibitors,in order to provide theoretical basis and new ideas for the research and development of new PARP7 inhibitors and the structural optimization of RBN-2397.
